Reports on response of invasive HER2-positive breast cancer have identified similar factors, as complete response is more frequently observed in patients treated with dual HER2-blockade compared to trastuzumab alone, in patients with a (near) complete response on MRI or in IBC with a high Ki-67 expression [4–6, 8, 34, 35]. The gene discussed is ERBB2; the disease is inflammatory breast carcinoma.